The most specific finding is tender or thickened temporal arteries with decreased ... or rarely over the orbits. Giant cell arteritis is a systemic vasculitis and careful attention should be ...

AbbVie’s Rinvoq (upadacitinib) has been granted marketing authorisation by the European Commission (EC) to treat giant cell ...

Find effective medications for 'Temporal Arteritis treatment right here!' This page is a trusted source for both professionals and patients, detailing brand-name and generic options designed to ...

Giant-cell arteritis is a systemic vasculitis with limited treatment options. The efficacy and safety of upadacitinib — a ...

Unlike PMR, temporal arteritis requires immediate medical attention. Delays in treatment might have major repercussions, such as blindness or stroke. As per the Arthritis Foundation, If you are ...

While treatment-associated complications are ... Visual loss is a serious complication in temporal arteritis. Involvement of extracranial arteries and aorta is certainly under-recognized at ...

The European Commission (EC) has granted marketing authorisation for AbbVie's once-a-day treatment Rinvoq (upadacitinib) 15mg ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis ... of the temporal and other cranial arteries ...

Patients should be clinically monitored, and alternative treatment should be considered if there is an inadequate therapeutic response. Giant Cell Arteritis RINVOQ monotherapy should not be used ...